Alendronate or Alfacalcidol in Glucocorticoid-Induced Osteoporosis
Open Access
- 17 August 2006
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 355 (7) , 675-684
- https://doi.org/10.1056/nejmoa053569
Abstract
Treatment with glucocorticoids is associated with bone loss starting soon after therapy is initiated and an increased risk of fracture.Keywords
This publication has 30 references indexed in Scilit:
- Corticosteroid use and risk of hip fracture: a population‐based case–control study in DenmarkJournal of Internal Medicine, 2003
- The Epidemiology of Corticosteroid-Induced Osteoporosis: a Meta-analysisOsteoporosis International, 2002
- The Role of Parathyroid Hormone in the Pathogenesis of Glucocorticoid-Induced Osteoporosis: A Re-Examination of the EvidenceJournal of Clinical Endocrinology & Metabolism, 2002
- Mechanisms of Glucocorticoid Action in BoneAnnals of the New York Academy of Sciences, 2002
- Prevalence of vertebral deformities and symptomatic vertebral fractures in corticosteroid treated patients with rheumatoid arthritisRheumatology, 2001
- Use of Oral Corticosteroids and Risk of FracturesJournal of Bone and Mineral Research, 2000
- New Developments in the Pathogenesis and Treatment of Steroid-Induced OsteoporosisJournal of Bone and Mineral Research, 1999
- Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids.Annals of the Rheumatic Diseases, 1986
- Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapyMetabolism, 1983
- Intestinal Calcium Absorption in Exogenous HypercortisonismJournal of Clinical Investigation, 1977